Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 391

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 391
---
 for issuance under the 2024 Plan and the number
of shares that may be issued pursuant to incentive stock options, by an additional shares each. At a special meeting of stockholders
on November 11, 2024, the stockholders approved an increase in the number of shares available for issuance under the 2024 Plan and the
number of shares that may be issued pursuant to incentive stock options, by an additional shares each. As of December 31, 2024,
no awards have been granted under the 2024 ESPP. The 2024 Plan has an evergreen provision that allows for an annual increase in the number
of shares available for issuance under the 2024 Plan to be added on the first day of January, starting with January 1, 2025, in an amount
equal to the lesser of (i) % of the fully diluted shares of our Common Stock on the immediately preceding December 31 or (ii) such number
of shares as determined by our board in each case subject to adjustment in the event of a stock split, stock dividend or other change
in our capitalization. On January 1, 2025, the number of shares reserved under the 2024 Plan was increased by % of the fully diluted
shares of our common stock on the immediately preceding December 31, or shares. The 2024 ESPP has an evergreen provision that allows
for an annual increase in the number of shares available for issuance under the 2024 ESPP to be added on the first day of each January,
starting with January 1, 2025, by the lesser of (i) shares of our common stock, (ii) % of the fully diluted shares of common stock
on the immediately preceding December 31, or (iii) such number of shares of common stock as determined by our board. The number of shares
reserved under the 2024 ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization.
As of December 31, 2024, the board of directors has granted an aggregate of option awards under the 2024 Plan, leaving shares
reserved for future issuance under the 2024 Plan.

The Company estimated the
fair value of stock options granted during the period February 14, 2024 through December 31, 2024 using Black-Scholes with the following
weighted average assumptions:

| ● | The Common Stock expected dividend yield assumption of